APBA1
-
Official Full Name
amyloid beta (A4) precursor protein-binding, family A, member 1
-
Overview
component of multimeric complex containing Munc18-1 and syntaxin; may mediate synaptic vesicle docking/fusion -
Synonyms
APBA1; amyloid beta (A4) precursor protein-binding, family A, member 1; MINT1; amyloid beta A4 precursor protein-binding family A member 1; D9S411E; X11; mint-1; adapter protein X11alpha; adaptor protein X11alpha; neuron-specific X11 protein; neuronal mun;
- Recombinant Proteins
- Protein Pre-coupled Magnetic Beads
- Human
- Rat
- E.Coli or Yeast
- HEK293
- In Vitro Cell Free System
- Mammalian Cell
- Wheat Germ
- GST
- His
- His (Fc)
- Avi
| Species | Cat.# | Product name | Source (Host) | Tag | Protein Length | Price |
|---|---|---|---|---|---|---|
| Human | APBA1-666H | Recombinant Human APBA1 protein, GST-tagged | Wheat Germ | GST |
|
|
| Human | APBA1-1077HF | Recombinant Full Length Human APBA1 Protein, GST-tagged | In Vitro Cell Free System | GST | 837 amino acids |
|
| Rat | APBA1-707R | Recombinant Rat APBA1 Protein | Mammalian Cell | His |
|
|
| Rat | Apba1-3434R | Recombinant Rat Apba1, His-tagged | E.Coli or Yeast | His | 839 |
|
| Rat | APBA1-363R | Recombinant Rat APBA1 Protein, His (Fc)-Avi-tagged | HEK293 | His (Fc)-Avi |
|
|
| Rat | APBA1-363R-B | Recombinant Rat APBA1 Protein Pre-coupled Magnetic Beads | HEK293 |
|
- Involved Pathway
- Protein Function
- Interacting Protein
- APBA1 Related Articles
APBA1 involved in several pathways and played different roles in them. We selected most pathways APBA1 participated on our site, such as Dopamine Neurotransmitter Release Cycle, Neuronal System, Neurotransmitter Release Cycle, which may be useful for your reference. Also, other proteins which involved in the same pathway with APBA1 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Dopamine Neurotransmitter Release Cycle | SYN1;PPFIA2;Apba1;RERG;LIN7C;PPFIA4;SYN3;CCDC167;CPLX1 |
| Neuronal System | ABCC9;CHRNB4;CHRNE;CACFD1;RAB3AB;STXBP1A;GNGT2B;CHRNA7;KCNK1B |
| Neurotransmitter Release Cycle | SLC17A7A;SLC1A3B;CPLX2L;SLC1A3A;RERG;PPFIA1;LIN7C;LIN7B;SYT1A |
| Transmission across Chemical Synapses | GABRR2A;ARL6IP5B;PPFIA1;SYN2;SNAP25B;CPLX2L;SLC18A3A;SLC1A2A;CACFD1 |
APBA1 has several biochemical functions, for example, PDZ domain binding, beta-amyloid binding, phosphatidylinositol-4,5-bisphosphate binding. Some of the functions are cooperated with other proteins, some of the functions could acted by APBA1 itself. We selected most functions APBA1 had, and list some proteins which have the same functions with APBA1. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| PDZ domain binding | LPAR2;FZD3;DLG3;GNG12;PROSAPIP1;ATP2B3A;SDC2;SLC9A3;GRIA1 |
| beta-amyloid binding | HBA-A2;LDLRAD3;CLSTN1;FBXO2;HSD17B10;APBB2;CHRNA7;APBA3;NGFR |
| phosphatidylinositol-4,5-bisphosphate binding | SNX18;RPH3A;TTPA;SCIN;LDLRAP1;SLC9A1;SYTL2;TULP1;STXBP6 |
| protein binding | UBE2K;UBE2D2;SUPT5H;MAP1LC3B;HNF4A;CCND2;CIB3;MRPS16;C9orf16 |
| protein complex binding | INS2;PTPRF;DAG1;HADHA;EPCAM;LRP1;FBLN1;GNB1;RARB |
APBA1 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with APBA1 here. Most of them are supplied by our site. Hope this information will be useful for your research of APBA1.
- Q&As
- Reviews
Q&As (20)
Ask a questionIn scientific research, recombinant APBA1 protein can be used to study the function, interaction and regulatory mechanism of APBA1, which is conducive to in-depth understanding of the pathogenesis of related diseases.
The recombinant APBA1 protein is not usually used to diagnose diseases, but for treatment and research.
The dosage needs to be determined according to the specific disease type, the patient's condition and the purpose for which the APBA1 is used. It is best to adjust the dosage under the guidance of a doctor.
The development of oral formulations is a challenging goal, but it is possible to achieve oral administration of APBA1 through technological advances in the future.
The use of APBA1 needs to be determined based on the specific disease and treatment regimen, and may require long-term use or intermittent use.
There are currently no APBA1 products that have passed clinical trials and been approved.
The manufacturing process of APBA1 requires strict quality standards to ensure the safety and effectiveness of the product.
At present, there are no reports of resistance of APBA1 , but the existence of individual differences cannot be ruled out.
When using APBA1 , it is necessary to pay attention to the interaction with other drugs, and to use the combination under the guidance of a doctor.
The time for the therapeutic effect of APBA1 varies from person to person, and the specific effect needs to be judged according to the patient's condition and medication.
There have been no clear reports of side effects of APBA1 , but it is still necessary to closely monitor the patient's condition and physiological indicators during use.
The function and efficacy of APBA1 may be different in patients from different regions, and further studies are needed to determine it.
The age limit for the use of APBA1 needs to be determined according to the specific disease and medication situation, and it is best to use under the guidance of a doctor.
Future studies may explore the development of an APBA1 drug for export, but further research and clinical trials are currently needed.
APBA1 should be stored in a dry, cool place and avoid exposure to direct sunlight.
APBA1 is a recombinant synthetic protein that has a similar function to the protein encoded by the APBA1 gene.
The recombinant APBA1 protein can be used to treat diseases associated with APBA1, such as neurodegenerative diseases and cognitive disorders.
In the course of the treatment of APBA1 , it is generally necessary to regularly monitor the relevant disease and physiological indicators, and adjust the dose and treatment plan.
APBA1 is still in the research stage, and more clinical data and research evidence are needed to determine whether it can replace traditional treatment methods.
At present, the treatment for APBA1-related diseases is still in the research stage, and the success rate needs to be further explored and verified.
Customer Reviews (4)
Write a reviewProduction process of APBA1 focuses on sustainable development, and maximizes the use of energy and resources by optimizing the production process and equipment, which is very environmentally friendly.
Due to the short half-life and high clearance of recombinant protein, it can better adapt to the treatment needs of patients of different ages and physiological states.
The stability of the experiment with this protein is very good, which greatly reduces the error of the experiment and improves the accuracy of the experiment.
Stability and repeatability of APBA1 is truly impressive! Regardless of the environment, it can maintain stable performance, making scientific research results more reliable.
Ask a Question for All APBA1 Products
Required fields are marked with *
My Review for All APBA1 Products
Required fields are marked with *
